Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease

NCT07753200 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT07753200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07753200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
Lead sponsor
Samsung Medical Center
Phase
Phase 4
Overall status
Recruiting
Start date
July 20, 2026
Completion date
December 31, 2031
Enrollment
3,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation (af), coronary arterial disease (cad)